OncoMatch/Clinical Trials/NCT06131840
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Is NCT06131840 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for colorectal neoplasms.
Treatment: PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) · Oxaliplatin · Leucovorin (LV) — This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Participants in this study must have cancer that has come back or did not get better with treatment. Participants must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08046050. PF-08046050 is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will test the safety of PF-08046050 in participants with solid tumors that are hard to treat or have spread throughout the body. This study has 5 different study parts. Part A and Part B of the study will find out how much PF-08046050 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046050 is safe and if it works to treat certain solid tumor cancers. Part D and E of the study, together with information from Parts A and B, will find out how much PF-08046050 should be given in combination with other anti-cancer agents. Part E will use the information from Parts A, B, and D to see if PF-08046050 is safe in combination with other anti-cancer agents and if it works to treat a certain solid tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Gastric Cancer
Esophageal Carcinoma
Small Cell Lung Cancer
Biomarker criteria
Excluded: CEACAM5 prior CEACAM5-targeted therapy
Previous exposure to CEACAM5-targeted therapy
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — NSCLC, SCLC, GC, GEJ
must have received platinum-based therapy
Must have received: fluoropyrimidine-based chemotherapy — GC, GEJ
must have received prior platinum and fluoropyrimidine-based chemotherapy
Must have received: PD-1/PD-L1 inhibitor — NSCLC, SCLC
must have received a PD-1/PD-L1 inhibitor if eligible and consistent with local standard of care
Must have received: targeted therapy — NSCLC with tumor genomic mutations/alterations for which approved targeted therapies are available
participants with tumor genomic mutations/alterations for which approved targeted therapies are available per local standard of care, must have received such therapies
Cannot have received: TOPO1 inhibitor (irinotecan, nanoliposomal irinotecan)
must not have received a prior TOPO1 inhibitor (such as irinotecan or nanoliposomal irinotecan) in any setting
Cannot have received: TOPO1-targeting ADC (CPT payload) (trastuzumab deruxtecan, sacituzumab govitecan)
Prior treatment with a TOPO1-targeting ADC (CPT payload), such as Enhertu (trastuzumab deruxtecan) or Trodelvy (sacituzumab govitecan)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Hospital · Phoenix, Arizona
- Mayo Clinic · Scottsdale, Arizona
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) · Duarte, California
- IP Address: City of Hope Investigational Drug Services(IDS) · Duarte, California
- University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify